ATXS — Astria Therapeutics, Inc. Common Stock

XNAS · Healthcare · Biotechnology

Price $12.51

Market Cap $706.0M

P/E —

52W Range $3.56 – $12.71

About Astria Therapeutics, Inc. Common Stock

Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.